Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) with a maintained price target of $110.
April 25, 2024 | 2:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald reaffirmed an Overweight rating on Biomarin Pharmaceutical with a $110 price target.
The reiteration of an Overweight rating by a reputable analyst firm like Cantor Fitzgerald, along with a maintained price target of $110, suggests a positive outlook for Biomarin Pharmaceutical. This endorsement could lead to increased investor confidence in BMRN, potentially driving up its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100